{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:37:33Z","timestamp":1785299853377,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bulcan.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:37:49Z","timestamp":1638783469000},"page":"S90-S97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S","title":["Prise en charge prophylactique, th\u00e9rapeutique des complications infectieuses et vaccination des patients trait\u00e9s par CAR-T cells\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"108","author":[{"given":"Franciane","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2933-5069","authenticated-orcid":false,"given":"Anne-Sophie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sterin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-8106","authenticated-orcid":false,"given":"Jean-Jacques","family":"Tudesq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2021.11.001_bib0150","first-page":"62","article-title":"Beginning the CAR T cell therapy revolution in the US and EU","volume":"66","author":"Grupp","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"10.1016\/j.bulcan.2021.11.001_bib0155","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2021.11.001_bib0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2021.11.001_bib0165","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.11.001_bib0170","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"10.1016\/j.bulcan.2021.11.001_bib0175","first-page":"93","article-title":"Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.11.001_bib0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bulcan.2021.11.001_bib0185","unstructured":"TECARTUS (brexucabtagene autoleucel) 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel."},{"issue":"8","key":"10.1016\/j.bulcan.2021.11.001_bib0190","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2021.11.001_bib0195","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bulcan.2021.11.001_bib0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jmii.2021.02.006","article-title":"Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy","volume":"54","author":"Beauvais","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.bulcan.2021.11.001_bib0205","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-Cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2021.11.001_bib0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.11.001_bib0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12879-020-05755-4","article-title":"Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy \u2013 a case report","volume":"21","author":"Rejeski","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.bulcan.2021.11.001_bib0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2\u00a0trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2021.11.001_bib0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bulcan.2021.11.001_bib0230","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19\u00a0CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"11S","key":"10.1016\/j.bulcan.2021.11.001_bib0235","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2021.11.001_bib0240","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.11.001_bib0245","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2021.11.001_bib0250","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bulcan.2020.11.014","article-title":"[How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC]","volume":"108","author":"Carnoy","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2021.11.001_bib0255","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.bulcan.2021.11.001_bib0260","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2021.11.001_bib0265","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19\u00a0CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.bulcan.2021.11.001_bib0270","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.bulcan.2021.11.001_bib0275","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2021.11.001_bib0280","first-page":"100596","article-title":"CAR-T - and a side order of IgG, to go?","volume":"38","author":"Hill","year":"2019","journal-title":"- Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev"},{"issue":"3","key":"10.1016\/j.bulcan.2021.11.001_bib0285","first-page":"111","article-title":"CAR T-cell treatment during the COVID-19\u00a0pandemic: Management strategies and challenges","volume":"68","author":"Hu","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.bulcan.2021.11.001_bib0145","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512100446X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512100446X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:19Z","timestamp":1762104019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512100446X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S000745512100446X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.11.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge prophylactique, th\u00e9rapeutique des complications infectieuses et vaccination des patients trait\u00e9s par CAR-T cells\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}